Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02954653 · ClinicalTrials.gov registry record · Phase 1
A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02954653 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 8 participants.
The verdict
NCT02954653, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
Two part, dose escalation and dose expansion study. Open label, multi center, non randomized, multiple dose, safety, pharmacokinetic and pharmacodynamic study of single agent PF-06747143 in sequential dose levels of adult patients with refractory or relapsed AML in order to establish maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D) or maximally permitted dose (MPD) following by a 3 arm dose expansion with PF-06747143 in combination with standard of care chemotherapy in adult patients with AML.
Interventions
- DRUG Azacitidine
- DRUG Decitabine
- DRUG Cytarabine
- DRUG Daunorubicin
- BIOLOGICAL PF-06747143
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2016-11-28 |
| Est. Completion | 2017-12-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02954653
The ClinicalTrials.gov registry entry for NCT02954653 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Azacitidine is the first listed.
NCT02954653 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02954653 about?
NCT02954653 is a clinical study titled "A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia". Two part, dose escalation and dose expansion study. Open label, multi center, non randomized, multiple dose, safety, pharmacokinetic and pharmacodynamic study of single agent PF-06747143 in sequential dose levels of adult patients with refractory or relapsed AML in order to establish maximum tolerat...
What is the current status of trial NCT02954653?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2016-11-28. Estimated completion is 2017-12-05.
What interventions are being tested in trial NCT02954653?
The interventions under investigation include: Azacitidine (DRUG), Decitabine (DRUG), Cytarabine (DRUG), Daunorubicin (DRUG), PF-06747143 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02954653?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.